Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Drug Discovery World

JANUARY 12, 2023

The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. . What are organoids? .

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

XTalks

SEPTEMBER 30, 2020

In collaboration with clinicians around the world, Casanova’s team studied the genomes of COVID-19 patients, focusing on a set of 13 genes involved in interferon immunity against influenza. percent) of the critically ill patients harbored rare mutations in eight of the genes involved in interferon production. percent of men.

Antibody 135

Antibody Genetics Research In-Vitro 135

Drug Discovery World

DECEMBER 12, 2022

The meeting will focus on the application of genome engineering in identification of novel drug targets through large-scale CRISPR based functional genomics studies, developing advanced cellular and in vivo disease models for target validation, and its applications in therapeutic genome editing. Register here.

Genome 52

Genome Genomics Engineer In-Vivo 52

pharmaphorum

MARCH 15, 2022

Gene sequencing specialist Illumina has started rolling out a new test that looks for a battery of tumour-associated genes from a single tissue sample, and could be used to help guide treatment for a broad range of cancers. “Comprehensive genomic profiling has proven to be this platform.”

Gene 52

Gene Genome Genomics Gene Sequencing 52

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Such information can reveal details about tumor staging, tumor progression, heterogeneity, gene mutations and clonal evolution. In addition, liquid biopsy is a minimally invasive technology and has a much lower risk compared to tissue biopsy procedures.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

OCTOBER 26, 2021

The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science. Cancer is a disease of the genome and treatment no longer depends solely on the tissue of origin.

Genome 52

Genome Genomics Research Medicine 52

XTalks

AUGUST 12, 2020

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA 52

RNA Protein DNA In-Vivo 52

The Pharma Data

AUGUST 27, 2020

FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers. FoundationOne Liquid CDx adds to Foundation Medicine’s genomic testing portfolio supporting Roche’s mission to deliver truly personalised healthcare.

FDA Approval 52

FDA Approval Genome Genomics Gene 52

Roots Analysis

MARCH 16, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. mRNA-based therapeutics and vaccines can be delivered via the below-mentioned approaches.

Vaccination 52

Vaccination Vaccine DNA Protein 52

The Pharma Data

SEPTEMBER 16, 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Join this event on Roche’s LinkedIn page here. Roche highlights featured at ESMO Virtual Congress 2020.

HR 52

HR Medicine Hormones Trials 52

Pharmaceutical Technology

AUGUST 26, 2008

“However, around the time of the Human Genome Project, there was a ‘land grab’ for the new technologies as big pharmaceuticals tried to catch up paying high prices to access technology platforms in areas such as genomics and high throughput screening.” “Biotechnology has exploded across the industry. .

Antibody 130

Antibody Licensing Licensing Production 130

Drug Discovery World

JANUARY 23, 2023

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies. Adult fibroblasts were cultured in a cocktail of transcription factors to reactivate embryonic gene expression patterns 2.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

Drug Discovery World

JANUARY 17, 2024

CTCs reflect high levels of tumour heterogeneity, represent clonal evolution, and are suitable for treatment selection, real-time longitudinal disease monitoring and in vitro/in vivo culture. Brett Swansiger, Chief Commercial Officer at ANGLE discusses the importance of liquid biopsies in precision medicine trials for cancer.

Medicine 59

Medicine DNA Genome Genomics 59

Drug Discovery World

FEBRUARY 28, 2023

Finally, dosing and timing may be controlled simply by adjusting the amount of mRNA delivered to the cells, rather than relying on inducible systems that are integrated into the genome. Approximately 7,000 rare and ultra-rare diseases have been described, and yet, 90% have no approved therapeutic options 1.

Genetics 52

Genetics Genetic Analysis Vaccination Vaccine 52

The Pharma Data

SEPTEMBER 28, 2021

Real-time PCR technology allows a rapid and specific measurement of the presence of genes from microorganisms related to infectious diseases, cancer, and genetic abnormalities. Roche is additionally the planet leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Marketing 52

Marketing In-Vitro DNA Bacteria 52

The Pharma Data

NOVEMBER 17, 2021

Streamlined in vitro data, published in bioRxiv, demonstrate that sotrovimab retains exertion against all current variants of concern and interest of the SARS-CoV-2 contagion as defined by the World Health Organization, plus others, including, but not limited to, Delta (B.1.617.2), 1.617.2), Delta Plus (AY.1 2) and Mu (B.1.621).

Antibody 52

Antibody In-Vitro Vaccination Vaccine 52

Drug Discovery World

APRIL 21, 2023

The 2022 podium winner was Viktoria Zieger, Imtek – University of Freiburg, who presented: Selective High- Throughput Deposition of Microtumors for in vitro Studies on 3D Tumor Models. SLAS Europe 2023 will take place 22-26 May in Brussels, Belgium, where attendees will embrace the theme Science Set in Motion.

Doctors 52

Doctors Doctor Genetics In-Vitro 52

Drug Discovery World

OCTOBER 17, 2022

For pharma and biotech companies – whether working on small or large molecule drugs, or cell and gene therapies – this means empowering scientists with better and faster data management approaches, best practices, and leading technologies so they can pinpoint new molecules and formulations and modify existing ones more easily and quickly.

Marketing 52

Marketing Scientist Gene Expression Drugs 52

The Pharma Data

JANUARY 24, 2021

Brilacidin has shown in vitro to be have antiviral properties against different SARS-CoV-2 strains and other human coronaviruses. With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see. COVID-19-Related. Non-COVID-19-Related.

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

MARCH 26, 2021

New in vitro data from pseudotyped virus assays published online in bioRxiv in March 2021 support this hypothesis as they demonstrate that VIR-7831 maintains activity against current circulating variants of concern including the UK, South African and Brazilian variants. About the VIR-7831 Clinical Development Programme.

Antibody 52

Antibody Trials Vaccination Vaccine 52

Pharmaceutical Technology

FEBRUARY 20, 2023

He says these issues must be urgently addressed over the next few years as advancing medical knowledge and the role of genomics in treating disease ushers in a new era of precision medicine and new potential to address diseases that affect certain populations. This may sound obvious, but it is still a major hurdle in drug development.

Research 130

Research Clinical Trials Clinical Trials Trials 130